Citations

Clear

4610 citation(s) found for "Lu, Brian".

Diffuse Diseases of the Myocardium: MRI-Pathologic Review of Cardiomyopathies With Dilatation
Giesbrandt, Kirk J., Bolan, Candice W. , Shapiro, Brian P. , Edwards, William D. , Mergo, Patricia J.

Mayo Clinic

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: W274-W282

10.2214/ajr.12.9634 | PMID 23436872 Get It

Diffuse Diseases of the Myocardium: MRI-Pathologic Review of Nondilated Cardiomyopathies
Giesbrandt, Kirk J., Bolan, Candice W. , Shapiro, Brian P. , Edwards, William D. , Mergo, Patricia J.

Mayo Clinic

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: W266-W273

10.2214/ajr.12.9633 | PMID 23436871 Get It

Serial infusions of low-dose ketamine for major depression
Rasmussen, Keith G., Lineberry, Timothy W., Galardy, Christine W., Kung, Simon , Palmer, Brian A. , Ritter, Matthew J. , Schak, Kathryn M. , Sola, Christopher L., Hanson, Allison J, Frye, Mark A. , Lapid, Maria I.

Mayo Clinic

Journal of Psychopharmacology | February 21, 2013 | Volume: 27 | Issue: 5 | Pages: 444-450

10.1177/0269881113478283 | PMID 23428794 Get It

Background: Single infusions of ketamine have been used successfully to achieve improvement in depressed patients. Side effects during the infusions have been common. It is not known whether serial infusions or lower infusion rates result in greater efficacy. Methods: Ten depressed patients were treated with twice weekly ketamine infusions of ketamine 0.5 mg/kg administered over 100 min until either remission was achieved or four infusions were given. Side effects were assessed with the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS). Patients were followed naturalistically at weekly intervals for four weeks after completion of the infusions. Results: Five of 10 patients achieved remission status. There were no significant increases on the BPRS or YMRS. Two of the remitting patients sustained their improvement throughout the four week follow-up period. Conclusions: Ketamine infusions at a lower rate than previously reported have demonstrated similar efficacy and excellent tolerability and may be more practically available for routine clinical care. Serial ketamine infusions appear to be more effective than a single infusion. Further research to test relapse prevention strategies with continuation ketamine infusions is indicated.
Lipomas of the cerebellopontine angle and internal auditory canal
White, James R. , Carlson, Matthew L. , Neff, Brian A., Driscoll, Colin L. W., Lane, John I. , Link, Michael J., Gompel, Jamie J. Van

Mayo Clinic

The Laryngoscope | February 10, 2013 | Volume: 123 | Issue: 6 | Pages: 1531-1536

10.1002/lary.23882 | PMID 23401141 Get It

Objectives/HypothesisTo describe the presentation and clinical course of cerebellopontine angle (CPA) and internal auditory canal (IAC) lipomas.Study DesignRetrospective cohort study at a tertiary academic referral center.MethodsAll patients presenting with a CPA or IAC mass radiographically consistent with a lipoma on high‐resolution magnetic resonance imaging (MRI) were identified. Data including presenting symptomatology, tumor characteristics, management strategy, and patient course were collected.ResultsBetween 1996 and 2012, 15 patients were diagnosed with a CPA or IAC lipoma at the authors' institution and were included in the analysis. The mean duration of radiological and clinical follow‐up was 3.4 years and 5.1 years, respectively. Eight lesions were confined to the IAC, while seven involved the CPA. The median tumor size at diagnosis was 7.2 mm; one patient demonstrated tumor growth on serial MRI while the remaining subjects did not have radiological progression. The most common presenting symptoms were sensorineural hearing loss (40%) and tinnitus (33%); five patients were diagnosed after incidental discovery on MRI. Fourteen patients were managed with observation, while one subject underwent subtotal resection. None of the observed patients reported worsening symptoms at last follow‐up.ConclusionsWhile rare, lipomas should be included in the differential diagnosis of CPA and IAC lesions. Owing to a generally benign clinical course and high morbidity associated with resection, microsurgery should only be considered in cases of definite tumor enlargement with intractable symptoms from mass effect. Careful radiological evaluation is critical for establishing an accurate diagnosis in order to prevent unnecessary morbidity associated with resection.Level of Evidence2b.
Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement
Trost, Landon , Şerefoğlu, Ege Can , Gökçe, Ahmet , Linder, Brian J. , Sartor, Alton Oliver, Hellstrom, Wayne J.G. , Linder, Brian J

Mayo Clinic

The Journal of Sexual Medicine | February 6, 2013 | Volume: 10 | Issue: Supplement_1 | Pages: 84-101

10.1111/jsm.12036 | PMID 23387914 Get It

ABSTRACTIntroductionAndrogen deprivation therapy (ADT) is commonly utilized in the management of both localized and advanced adenocarcinoma of the prostate. The use of ADT is associated with several adverse events, physical changes, and development of medical comorbidities/mortality.AimThe current article reviews known adverse events associated with ADT as well as treatment options, where available. Current recommendations and guidelines are cited for ongoing monitoring of patients receiving ADT.MethodsA PubMed search of topics relating to ADT and adverse outcomes was performed, with select articles highlighted and reviewed based on level of evidence and overall contribution.Main Outcome MeasuresReported outcomes of studies detailing adverse effects of ADT were reviewed and discussed. Where available, randomized trials and meta-analyses were reported.ResultsADT may result in several adverse events including decreased libido, erectile dysfunction, vasomotor symptoms, cognitive, psychological and quality of life impairments, weight gain, sarcopenia, increased adiposity, gynecomastia, reduced penile/testicular size, hair changes, periodontal disease, osteoporosis, increased fracture risk, diabetes and insulin resistance, hyperlipidemia, and anemia. The definitive impact of ADT on lipid profiles, cardiovascular morbidity/mortality, and all-cause mortality is currently unknown with available data. Treatment options to reduce ADT-related adverse events include changing to an intermittent treatment schedule, biophysical therapy, counseling, and pharmacotherapy.ConclusionsPatients treated with ADT are at increased risk of several adverse events and should be routinely monitored for the development of potentially significant morbidity/mortality. Where appropriate, physicians should reduce known risk factors and counsel patients as to known risks and benefits of therapy.
Spillover of Fatty Acids During Dietary Fat Storage in Type 2 Diabetes
Almandoz, Jaime P. , Howell, Lisa , Grothe, Karen, Vlazny, Danielle T. , Smailovic, Almira, Irving, Brian A. , Miles, John M., Singh, Ekta , Nelson, Robert H. , Miles, John M.

Mayo Clinic

Diabetes | January 25, 2013 | Volume: 62 | Issue: 6 | Pages: 1897-1903

10.2337/db12-1407 | PMID 23349503 Get It

Spillover of lipoprotein lipase-generated fatty acids from chylomicrons into the plasma free fatty acid (FFA) pool is an important source of FFA and reflects inefficiency in dietary fat storage. We measured spillover in 13 people with type 2 diabetes using infusions of a [3H]triolein-labeled lipid emulsion and [U-13C]oleate during continuous feeding, before and after weight loss. Body fat was measured with dual energy X-ray absorptiometry and computed tomography. Participants lost ∼14% of body weight. There was an ∼38% decrease in meal-suppressed FFA concentration (P < 0.0001) and an ∼23% decrease in oleate flux (P = 0.007). Fractional spillover did not change (P = NS). At baseline, there was a strong negative correlation between spillover and leg fat (r = −0.79, P = 0.001) and a positive correlation with the trunk-to-leg fat ratio (R = 0.56, P = 0.047). These correlations disappeared after weight loss. Baseline leg fat (R = −0.61, P = 0.027) but not trunk fat (R = −0.27, P = 0.38) negatively predicted decreases in spillover with weight loss. These results indicate that spillover, a measure of inefficiency in dietary fat storage, is inversely associated with lower body fat in type 2 diabetes.
Association of Microvascular and Capillary-Lymphatic Invasion with Outcome in Patients with Renal Cell Carcinoma
Eisenberg, Manuel S., Cheville, John C. , Thompson, R. Houston, Kaushik, Dharam , Lohse, Christine M. , Boorjian, Stephen A. , Costello, Brian A. , Leibovich, Bradley C.

Mayo Clinic

Journal of Urology | January 23, 2013 | Volume: 190 | Issue: 1 | Pages: 37-43

10.1016/j.juro.2013.01.044 | PMID 23353044 Get It

Primary inner ear schwannomas: A case series and systematic review of the literature
Abel, Kathryn M. Van , Carlson, Matthew L. , Link, Michael J. , Neff, Brian A., Beatty, Charles W., Lohse, Christine M. , Eckel, Laurence J. , Lane, John I. , Driscoll, Colin L. W., Van Abel, Kathryn M

Mayo Clinic

The Laryngoscope | January 18, 2013 | Volume: 123 | Issue: 8 | Pages: 1957-1966

10.1002/lary.23928 | PMID 23335152 Get It

Objectives/HypothesisTo describe the natural history of primary inner ear schwannomas (PIES) and evaluate management outcomes and relationship between PIES location, clinical presentation, and time to diagnosis.Study DesignRetrospective chart review and systematic review of the literature.MethodsVestibular schwannoma confined to or arising from the inner ear were included. PIES classification was based on anatomic subsite(s) involved. Detailed clinical history and outcomes were recorded.ResultsIn a systematic review (1933–2011), including 14 patients from the authors' institution (1999–2009), a total of 72 studies comprising 234 patients were evaluated. Mean follow‐up was 32.8 ± 39.1 months (range, 0–183 months). The cochlea was the most commonly involved subsite (51%). Hearing loss was the most frequent presenting symptom (99%). Vertigo and abnormal balance were more common among tumors involving the vestibular system (P < .01). Average delay between symptom onset and diagnosis was 7.0 ± 8.0 years (median, 5 years; range, 0–40 years). Recent onset hearing loss was more likely to elicit an earlier diagnosis (P = .01). The majority of patients were observed without treatment (53%). Tumor progression was seen in 52% of patients.Conclusions PIES are rare tumors and most commonly involve the cochlea. Tumor location is often associated with clinical presentation and correlates with delay between symptom onset and diagnosis. A watch‐and‐scan approach is the management strategy of choice in the absence of intractable vertigo or extensive tumor growth. The majority of patients report stable or improved symptoms over time, regardless of treatment. Laryngoscope, 123:1957–1966, 2013
Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
Achenbach, Sara J., Asmann, Yan W. , Camp, Nicola J. , Rabe, Kari G. , Goldin, Lynn R. , Call, Timothy G. , Cunningham, Julie M. , Wang, Alice H., Weinberg, J. Brice , Norman, Aaron D. , Link, Brian K. , Leis, José F., Vachon, Celine M. , Lanasa, Mark C., Caporaso, Neil E., Novak, Anne J. , Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D. , Kay, Neil E. , Vachon, Celine M. , Chaffee, Kari G. , Cerhan, James R , Link, Brian K , Norman, Aaron D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2013 | Volume: 22 | Issue: 3 | Pages: 461-466

10.1158/1055-9965.epi-12-1217 | PMID 23307532 Get It

Abstract Background: Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk. Methods: To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes. Results: The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3′ untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81 × 10−6). This SNP was not associated with the other NHL subtypes (all P &gt; 0.05). Conclusions: We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology. Impact: These data provide support that a functional variant within the 3′UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk. Cancer Epidemiol Biomarkers Prev; 22(3); 461–6. ©2013 AACR.
Fasciotomy and Surgical Tenotomy for Recalcitrant Lateral Elbow Tendinopathy
Mohan, P.C., Howe, Tet Sen , Chia, Shi‐Lu, Yang, Zixian , Morrey, B.F. , Koh, Joyce Suang Bee , Mohan, P.C., Lee, Brian P.

Mayo Clinic

The American Journal of Sports Medicine | January 10, 2013 | Volume: 41 | Issue: 3 | Pages: 636-644

10.1177/0363546512470625 | PMID 23302261 Get It

Background: The optimal choice for intervention for recalcitrant lateral elbow tendinopathy remains unclear as various treatment modalities have documented comparable results in the literature. Purpose: To explore the safety, tolerability, and early efficacy of a new minimally invasive mode of treatment that delivers focused, calibrated ultrasonic energy, effectively microresecting the pathological tendon and removing only pathological tissue. Study Design: Case series; Level of evidence, 4. Methods: Seven male and 13 female patients aged 33 to 65 years averaging 12.5 months (range, 4-48) of failed nonoperative therapy underwent the ultrasonic microresection procedure in an outpatient clinic setting. The procedure involved a sterile, ultrasound-guided percutaneous microresection with a proprietary device (TX1) performed through a stab incision under local anesthesia. The duration of the procedure and complications of the device or procedure were assessed. Outcome parameters included patient satisfaction; visual analog scale (VAS) pain scores; Disabilities of the Arm, Shoulder and Hand (DASH) scores at 1, 3, 6, and 12 months; and ultrasound assessment at 3 and 6 months. Results: The median duration for the sterile confirmatory ultrasound examination (phase 1) was 88.5 seconds (range, 39-211; SD, ±47.6), the median duration of the procedure proper (phase 2) was 10.1 minutes (range, 4.1-19.4; SD, ±3.7), and the median energy time (duration the TX1 device was activated) was 32.5 seconds (range, 18-58; SD, ±11.0). No complications were encountered. A significant improvement in VAS score (from 5.5 to 3.3; P < .001) occurred by 1 week, and significant improvements in both DASH-Compulsory (from 21.7 to 11.3; P = .001) and DASH-Work (from 25.0 to 6.3; P = .012) scores occurred by 1 month. The VAS scores further improved at 3, 6, and 12 months (from 2.0 to 1.0 to 0.50; P = .003 and .023). The DASH-Compulsory score improved significantly from 3 to 6 months (from 8.6 to 4.6; P = .003), and both the DASH-Compulsory and DASH-Work scores were sustained by 12 months. Sonographically reduced tendon thickness (19 patients), resolved or reduced hypervascularity (17 patients), and reduced hypoechoic area (18 patients) occurred by 6 months. Nineteen of the 20 patients (95%) expressed satisfaction with the procedure, with 9 patients being very satisfied with their overall experience at 6 months after the procedure, 10 patients somewhat satisfied, and 1 patient neutral. Conclusion: Ultrasonic microresection of diseased tissue with the TX1 device provides a focally directed, safe, specific, minimally invasive, and well-tolerated treatment for recalcitrant lateral elbow tendinopathy in an office-based or ambulatory surgical setting with good evidence of some level of efficacy in 19 of 20 patients (95%) that is sustained for at least 1 year.